A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection

Journal of Controlled Release

Volumn 172, Issue 1, 2013, Pages 144-151

  Amiram, M ^a   Luginbuhl, K M ^a   Li, X ^a   Feinglos, M N ^b   Chilkoti, A ^a  

^a Duke University   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug delivery; Elastin like polypeptide; Glucagon like peptide 1; Peptide; Subcutaneous depot

Indexed keywords

BLOOD GLUCOSE LEVEL; ELASTIN-LIKE POLYPEPTIDES; GLUCAGON-LIKE PEPTIDE-1; PROLONGED RELEASE; PROTEOLYTIC STABILITY; SUBCUTANEOUS DEPOT; SYSTEMIC CIRCULATION; THERMALLY RESPONSIVE;

BLOOD; DRUG DELIVERY; GLUCOSE; POLYPEPTIDES;

PEPTIDES;

ANTIDIABETIC AGENT; COMPLEMENTARY DNA; ELASTIN LIKE POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; HYBRID PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; SYNTHETIC DNA; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CIRCULAR DICHROISM; CIRCULATION TIME; CONJUGATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; IN VITRO STUDY; INJECTION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; RECEPTOR BINDING; RESTRICTION SITE; ROOM TEMPERATURE; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION;

DRUG DELIVERY; ELASTIN-LIKE POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE-1; PEPTIDE; SUBCUTANEOUS DEPOT;

AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; ELASTIN; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INJECTIONS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PHASE TRANSITION; RECOMBINANT FUSION PROTEINS;

EID: 84883514263     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.07.021     Document Type: Article

References (48)

1. N.P. Hays, P.R. Galassetti, and R.H. Coker Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions Pharmacol. Ther. 118 2008 181 191
2. P.L. Brubaker Minireview: update on incretin biology: focus on glucagon-like peptide-1 Endocrinology 151 2010 1984 1989
3. M.A. Nauck Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective Acta Diabetol. 35 1998 117 129
4. H.X. Hui, H.N. Zhao, and R. Perfetti Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes Diabetes Metab. Res. Rev. 21 2005 313 331 (Pubitemid 40945953)
5. L.L. Baggio, and D.J. Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157 (Pubitemid 46711096)
6. R.A. DeFronzo From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
7. J.J. Holst, T. Vilsboll, and C.F. Deacon The incretin system and its role in type 2 diabetes mellitus Mol. Cell. Endocrinol. 297 2009 127 136
8. P.L. Brubaker, and D.J. Drucker Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system Endocrinology 145 2004 2653 2659 (Pubitemid 38686211)
9. L.P. Miranda, K.A. Winters, C.V. Gegg, A. Patel, J. Aral, J. Long, J. Zhang, S. Diamond, M. Guido, S. Stanislaus, M. Ma, H. Li, M.J. Rose, L. Poppe, and M.M. Veniant Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity J. Med. Chem. 51 2008 2758 2765 (Pubitemid 351620797)
10. J.A. Lovshin, and D.J. Drucker Incretin-based therapies for type 2 diabetes mellitus Nat. Rev. Endocrinol. 5 2009 262 269
11. S. Madsbad, U. Kielgast, M. Asmar, C.F. Deacon, S.S. Torekov, and J.J. Holst An overview of once-weekly glucagon-like peptide-1 receptor agonists - available efficacy and safety data and perspectives for the future Diabetes Obes. Metab. 13 2011 394 407
12. M.S. Fineman, B.B. Cirincione, D. Maggs, and M. Diamant GLP-1 based therapies: differential effects on fasting and postprandial glucose Diabetes, obesity & metabolism 14 2012 675 688
13. M. Diamant, L. Van Gaal, S. Stranks, J. Northrup, D. Cao, K. Taylor, and M. Trautmann Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial Lancet 375 2010 2234 2243
14. J.G. Kim, L.L. Baggio, D.P. Bridon, J.P. Castaigne, M.F. Robitaille, L. Jette, C. Benquet, and D.J. Drucker Development and characterization of a glucagon-like peptide 1-albumin conjugate - the ability to activate the glucagon-like peptide 1 receptor in vivo Diabetes 52 2003 751 759 (Pubitemid 36323583)
15. Q. Wang, K. Chen, R. Liu, F. Zhao, S. Gupta, N. Zhang, and G.J. Prud'homme Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist PLoS One 5 2010 e12734
16. V. Schellenberger, C.W. Wang, N.C. Geething, B.J. Spink, A. Campbell, W. To, M.D. Scholle, Y. Yin, Y. Yao, O. Bogin, J.L. Cleland, J. Silverman, and W.P.C. Stemmer A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner Nat. Biotechnol. 27 2009 1186 11900
17. A.K. Banga Parenteral controlled delivery and pharmacokinetics of therapeutic peptides and proteins Therapeutic Peptides and Proteins 2005 CRC Press 177 227
18. M. Amiram, K.M. Luginbuhl, X. Li, M.N. Feinglos, and A. Chilkoti Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control Proc. Natl. Acad. Sci. U. S. A. 110 2013 2792 2797
19. D.E. Meyer, and A. Chilkoti Quantification of the effects of chain length and concentration on the thermal behavior of elastin-like polypeptides Biomacromolecules 5 2004 846 851 (Pubitemid 38702255)
20. T. Christensen, M. Amiram, S. Dagher, K. Trabbic-Carlson, M.F. Shamji, L.A. Setton, and A. Chilkoti Fusion order controls expression level and activity of elastin-like polypeptide fusion proteins Protein Sci. 18 2009 1377 1387
21. N.J. Greenfield Using circular dichroism spectra to estimate protein secondary structure Nat. Protoc. 1 2006 2876 2890
22. L.L. Baggio, Q. Huang, T.J. Brown, and D.J. Drucker A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis Diabetes 53 2004 2492 2500 (Pubitemid 39145610)
23. R.S. Surwit, C.M. Kuhn, C. Cochrane, J.A. McCubbin, and M.N. Feinglos Diet-induced type II diabetes in C57BL/6J mice Diabetes 37 1988 1163 1167 (Pubitemid 19035045)
24. D.J. Drucker Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis Mol. Endocrinol. 17 2003 161 171 (Pubitemid 36183142)
25. P.H. Hirel, J.M. Schmitter, P. Dessen, G. Fayat, and S. Blanquet Extent of N-terminal methionine excision from Escherichia coli proteins is governed by the side-chain length of the penultimate amino acid Proc. Natl. Acad. Sci. U. S. A. 86 1989 8247 8251 (Pubitemid 19286036)
26. E.G. Siegel, B. Gallwitz, G. Scharf, R. Mentlein, C. Morys-Wortmann, U.R. Folsch, J. Schrezenmeir, K. Drescher, and W.E. Schmidt Biological activity of GLP-1-analogues with N-terminal modifications Regul. Pept. 79 1999 93 102 (Pubitemid 29376393)
27. D.E. Meyer, and A. Chilkoti Genetically encoded synthesis of protein-based polymers with precisely specified molecular weight and sequence by recursive directional ligation: examples from the elastin-like polypeptide system Biomacromolecules 3 2002 357 367 (Pubitemid 34257157)
28. D.W. Urry, C.H. Luan, T.M. Parker, D.C. Gowda, K.U. Prasad, M.C. Reid, and A. Safavy Temperature of polypeptide inverse temperature transition depends on mean residue hydrophobicity J. Am. Chem. Soc. 113 1991 4346 4348
29. K. Trabbic-Carlson, L. Liu, B. Kim, and A. Chilkoti Expression and purification of recombinant proteins from Escherichia coli: comparison of an elastin-like polypeptide fusion with an oligohistidine fusion Protein Sci. 13 2004 3274 3284 (Pubitemid 39557797)
30. D.W. Urry Elastic molecular machines in metabolism and soft-tissue restoration Trends Biotechnol. 17 1999 249 257 (Pubitemid 29249012)
31. S.R. Ong, K.A. Trabbic-Carlson, D.L. Nettles, D.W. Lim, A. Chilkoti, and L.A. Setton Epitope tagging for tracking elastin-like polypeptides Biomaterials 27 2006 1930 1935 (Pubitemid 41759487)
32. D.E. Meyer, and A. Chilkoti Purification of recombinant proteins by fusion with thermally-responsive polypeptides Nat. Biotechnol. 17 1999 1112 1115 (Pubitemid 29533553)
33. L.B. Knudsen Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes J. Med. Chem. 47 2004 4128 4134 (Pubitemid 39045416)
34. K. Hupe-Sodmann, G.P. McGregor, R. Bridenbaugh, R. Goke, B. Goke, H. Thole, B. Zimmermann, and K. Voigt Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides Regul. Pept. 58 1995 149 156
35. M. Malm-Erjefalt, I. Bjornsdottir, J. Vanggaard, H. Helleberg, U. Larsen, B. Oosterhuis, J.J. van Lier, M. Zdravkovic, and A.K. Olsen Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase Drug Metab. Dispos. 38 2010 1944 1953
36. Y.S. Huang, Z. Chen, Y.Q. Chen, G.C. Ma, J.F. Shan, W. Liu, and L.F. Zhou Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris J. Pept. Sci. 14 2008 588 595 (Pubitemid 351736454)
37. S.Y. Chae, Y.G. Chun, S. Lee, C.H. Jin, E.S. Lee, K.C. Lee, and Y.S. Youn Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers J. Pharm. Sci. 98 2009 1556 1567
38. M. Zander, S. Madsbad, J.L. Madsen, and J.J. Holst Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830 (Pubitemid 34233752)
39. L.L. Baggio, J.G. Kim, and D.J. Drucker Chronic exposure to GLP-IR agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo Diabetes 53 2004 S205 S214
40. D. LeRoith, S.I. Taylor, and J.M. Olefsky Diabetes mellitus: a fundamental and clinical text 3rd ed. 2004 Lippincott Williams & Wilkins Philadelphia
41. Q.H. Wang, K. Chen, R. Liu, F. Zhao, S. Gupta, N.N. Zhang, and G.J. Prud'homme Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist PLoS One 5 2010
42. A.A. Kaspar, and J.M. Reichert Future directions for peptide therapeutics development Drug Discov. Today 2013 10.1016/j.drudis.2013.05.011
43. V.T. Chuang, U. Kragh-Hansen, and M. Otagiri Pharmaceutical strategies utilizing recombinant human serum albumin Pharm. Res. 19 2002 569 577 (Pubitemid 34553662)
44. J.M.E. Chee, and W. Chia Biology and therapeutic potential of GLP-1 in the treatment of diabetes Drug Discov. Today Dis. Mech. 2 2005 295 301
45. H.H. Kwak, W.S. Shim, S. Hwang, M.K. Son, Y.J. Kim, T.H. Kim, Z.H. Yoon, H.J. Youn, G.I. Lee, S.H. Kang, and C.K. Shim Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats Pharm. Res. 26 2009 2504 2512
46. C.H. Niu, and Y.Y. Chiu FDA perspective on peptide formulation and stability issues J. Pharm. Sci. 87 1998 1331 1334
47. M.S. Shive, and J.M. Anderson Biodegradation and biocompatibility of PLA and PLGA microspheres Adv. Drug Deliv. Rev. 28 1997 5 24 (Pubitemid 27497671)
48. S.S. Pai, R.D. Tilton, and T.M. Przybycien Poly(ethylene glycol)-modified proteins: implications for poly(lactide-co-glycolide)-based microsphere delivery AAPS J. 11 2009 88 98